drug · small molecule
iCIP
Phase 2updated 3mo agoby Chosa Oncology AB🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 7- drugPRV-1313 co-mentions · 3 sources
- drugcisplatin3 co-mentions · 3 sources
- drugPRV-2113 co-mentions · 3 sources
- drugcisplatin SR3 co-mentions · 3 sources
- tagOncology2 co-mentions · 1 sources
- companyVirginia Commonwealth University1 co-mentions · 1 sources
- companyNational Cheng-Kung University Hospital1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and mesothelioma and 135 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying iCIP
- phase3Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- phase3Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- phase2To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- phase3Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- phase2Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response
- phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- phase3A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- phase3Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
News(2)
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 3mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 3mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that